المؤلفون: Narayan, Rupa, Alfonso-Piérola, Ana, Donnellan, William, Abdul-Hay, Maher, Molero , Antonieta, Platzbecker, Uwe

المساهمون: Institut Català de la Salut, Narayan R Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Center for Leukemia, Boston, Massachusetts, USA. Alfonso Piérola A Clínica Universidad de Navarra Pamplona, Pamplona, Spain. Donnellan WB Hematology/Medical Oncology, Tennessee Oncology/Sarah Cannon Research Institute, Nashville, Tennessee, USA. Molero Yordi A Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Abdul-Hay M Division of Hematology & Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA. Platzbecker U Clinic and Polyclinic for Hematology, Cell Therapy and Hemostaseology, University Hospital in Leipzig, Leipzig, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Posologia, Immunoglobulines - Ús terapèutic, Leucèmia mieloide aguda - Tractament, Síndromes mielodisplàsiques - Tractament, DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myelodysplastic Syndromes, DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::síndromes mielodisplásicos, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada

وصف الملف: application/pdf

العلاقة: Clinical and Translational Science;17(3); https://doi.org/10.1111/cts.13742Test; Narayan R, Alfonso Piérola A, Donnellan WB, Molero Yordi A, Abdul-Hay M, Subklewe M, et al. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clin Transl Sci. 2024 Mar 18;17(3):e13742.; https://hdl.handle.net/11351/11284Test; 001186183900001

الإتاحة: https://doi.org/10.1111/cts.13742Test
https://hdl.handle.net/11351/11284Test

المؤلفون: Janku, Filip, Choong, Grace, Opyrchal, Mateusz, Dowlati, Afshin, Hierro Carbó, Cinta, Rodon, Jordi

المساهمون: Institut Català de la Salut, Janku F The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Choong GM Mayo Clinic Rochester, Department of Oncology, Rochester, MN, USA. Opyrchal M Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dowlati A University Hospitals of Cleveland, Cleveland, OH, USA. Hierro C Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Rodon J The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Proteïnes quinases - Inhibidors - Ús terapèutic, Càncer - Tractament, Posologia, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, Other subheadings::Other subheadings::/therapeutic use, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas, Otros calificadores::Otros calificadores::/uso terapéutico

وصف الملف: application/pdf

العلاقة: Cancers;16(6); https://doi.org/10.3390/cancers16061137Test; Janku F, Choong GM, Opyrchal M, Dowlati A, Hierro C, Rodon J, et al. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers (Basel). 2024 Mar 13;16(6):1137.; https://hdl.handle.net/11351/11287Test; 001191969900001

الإتاحة: https://doi.org/10.3390/cancers16061137Test
https://hdl.handle.net/11351/11287Test

المؤلفون: Lopez, Juanita, Lai-Kwon, Julia, Molife, L. R., Welsh, Liam, Tunariu, Nina, Roda, Desamparados, Azaro Pedrazzoli, Analía Beatriz, Rodon, Jordi

المساهمون: Institut Català de la Salut, Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D The Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK. Azaro A, Rodón J Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Gliomes - Tractament, Esfingolípids, Posologia, CHEMICALS AND DRUGS::Lipids::Membrane Lipids::Sphingolipids, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Glioma, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, COMPUESTOS QUÍMICOS Y DROGAS::lípidos::lípidos de membranas::esfingolípidos, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::glioma, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada

وصف الملف: application/pdf

العلاقة: British Journal of Cancer;129; https://doi.org/10.1038/s41416-023-02356-1Test; Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, et al. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. Br J Cancer. 2023 Sep 29;129:811–818.; https://hdl.handle.net/11351/10418Test; 001035687800003

الإتاحة: https://doi.org/10.1038/s41416-023-02356-1Test
https://hdl.handle.net/11351/10418Test

المؤلفون: Trippett, Tanya, Toledano, Helen, Campbell Hewson, Quentin, Verschuur, Arnauld, Langevin, Anne‑Marie, Gallego Melcón, Soledad, Aerts, Isabelle

المساهمون: Institut Català de la Salut, Trippett T Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA. Toledano H Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Campbell Hewson Q Department of Paediatric and Adolescent Oncology, The Great North Children’s Hospital, Newcastle Upon Tyne, UK. Verschuur A Assistance Publique-Hopitaux de Marseille, Pediatric Oncology, Timone Children’s Hospital, Marseille, France. Langevin AM Department of Pediatrics, UT Health San Antonio, San Antonio, TX, USA. Aerts I Oncology Center SIREDO, Institut Curie, PSL Research University, Paris, France. Gallego S Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Farmacocinètica, Posologia, Càncer - Tractament, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacokinetics, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::farmacocinética, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada

وصف الملف: application/pdf

العلاقة: Targeted Oncology;17(3); https://doi.org/10.1007/s11523-022-00888-9Test; Trippett T, Toledano H, Campbell Hewson Q, Verschuur A, Langevin AM, Aerts I, et al. Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study. Target Oncol. 2022 May;17(3):283–93.; https://hdl.handle.net/11351/8147Test; 000812474500002

الإتاحة: https://doi.org/10.1007/s11523-022-00888-9Test
https://hdl.handle.net/11351/8147Test

المؤلفون: Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Niccoli, Patricia, Curigliano, Giuseppe, Capdevila Castillon, Jaume

المساهمون: Institut Català de la Salut, Hollebecque A Gustave Roussy, Département d’innovation thérapeutique et essais précoces, Villejuif, France. Salvagni S S. Orsola Polyclinic, Malpighi University Hospital, Bologna, Italy. Plummer R Clinical and Translational Research Institute Northern, Newcastle University, Newcastle, UK. Niccoli P Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France. Capdevila J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. IOB-Teknon, Barcelona, Spain. Curigliano G European Institute of Oncology, IRCCS, University of Milan, Milan, Italy, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Posologia, Càncer - Tractament, Medicaments - Eficàcia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, DISEASES::Neoplasms, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, B-Cell, Marginal Zone, CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Oxidoreductases Acting on CH-NH Group Donors::Oxidoreductases, N-Demethylating::Histone Demethylases, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada, ENFERMEDADES::neoplasias, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B de la zona marginal, COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::oxidorreductasas::oxidorreductasas que actúan sobre donantes de grupos CH-NH::oxidorreductasas N-desmetilantes::histona desmetilasas

وصف الملف: application/pdf

العلاقة: Cancer;128(17); https://doi.org/10.1002/cncr.34366Test; Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, et al. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185–95.; https://hdl.handle.net/11351/8150Test; 000814787400001

الإتاحة: https://doi.org/10.1002/cncr.34366Test
https://hdl.handle.net/11351/8150Test

المؤلفون: Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Macarulla Mercadé, Teresa, Makker, Vicky

المساهمون: Institut Català de la Salut, Voss MH, Makker V Department of Medicine, 300 East 66th Street, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Gordon MS Oncology Research, HonorHealth Research Institute, 10510 N 92nd St Suite 200, Scottsdale, AZ 85258, USA. Mita M Department of Hematology and Oncology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd North Tower, Los Angeles, CA 90048, USA. Rini B Cleveland Clinic Foundation, Department of Solid Tumor Oncology, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Macarulla T Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Càncer - Tractament, Medicaments - Administració, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada

وصف الملف: application/pdf

العلاقة: British Journal of Cancer;123; https://doi.org/10.1038/s41416-020-01041-xTest; Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 Nov;123:1590–8.; https://hdl.handle.net/11351/6503Test; 000568843200001

الإتاحة: https://doi.org/10.1038/s41416-020-01041-xTest
https://hdl.handle.net/11351/6503Test